{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:31:33Z","timestamp":1791477093306,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01 HS024512"],"award-info":[{"award-number":["R01 HS024512"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K08 AG049684"],"award-info":[{"award-number":["K08 AG049684"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA201198"],"award-info":[{"award-number":["R01 CA201198"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data on osteoporosis and fractures in patients with thyroid cancer, especially men, are conflicting. Our objective was to determine osteoporosis and fracture risk in U.S. veterans with thyroid cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This is a case-control study using the Veterans Health Administration Corporate Data Warehouse (2004\u20132013). Patients with thyroid cancer (n = 10,370) and controls (n = 10,370) were matched by age, sex, weight, and steroid use. Generalized linear mixed-effects regression model was used to compare the two groups in terms of osteoporosis and fracture risk. Next, subgroup analysis of the patients with thyroid cancer using longitudinal thyroid-stimulating hormone (TSH) was performed to determine its effect on risk of osteoporosis and fractures. Other covariates included patient age, sex, median household income, comorbidities, and steroid and androgen use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Compared with controls, osteoporosis, but not fractures, was more frequent in patients with thyroid cancer (7.3% vs. 5.3%; odds ratio [OR], 1.33; 95% confidence interval [CI], 1.18\u20131.49) when controlling for median household income, Charlson\/Deyo comorbidity score, and androgen use. Subgroup analysis of patients with thyroid cancer demonstrated that lower TSH (OR, 0.93; 95% CI, 0.90\u20130.97), female sex (OR, 4.24; 95% CI, 3.53\u20135.10), older age (e.g., \u226585 years: OR, 17.18; 95% CI, 11.12\u201326.54 compared with &amp;lt;50 years), and androgen use (OR, 1.63; 95% CI, 1.18\u20132.23) were associated with osteoporosis. Serum TSH was not associated with fractures (OR, 1.01; 95% CI, 0.96\u20131.07).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Osteoporosis, but not fractures, was more common in U.S. veterans with thyroid cancer than controls. Multiple factors may be contributory, with low TSH playing a small role.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Data on osteoporosis and fragility fractures in patients with thyroid cancer, especially in men, are limited and conflicting. Because of excellent survival rates, the number of thyroid cancer survivors is growing and more individuals may experience long-term effects from the cancer itself and its treatments, such as osteoporosis and fractures. The present study offers unique insight on the risk for osteoporosis and fractures in a largely male thyroid cancer cohort. Physicians who participate in the long-term care of patients with thyroid cancer should take into consideration a variety of factors in addition to TSH level when considering risk for osteoporosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0234","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T20:39:09Z","timestamp":1559680749000},"page":"1166-1173","source":"Crossref","is-referenced-by-count":37,"title":["Risk of Osteoporosis and Fractures in Patients with Thyroid Cancer: A Case-Control Study in U.S. Veterans"],"prefix":"10.1093","volume":"24","author":[{"given":"Maria","family":"Papaleontiou","sequence":"first","affiliation":[{"name":"Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousumi","family":"Banerjee","sequence":"additional","affiliation":[{"name":"School of Public Health, Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reyes-Gastelum","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah T.","family":"Hawley","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Haymart","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"2021122507523206400_onco12999-bib-0001","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/theoncologist.2015-0179","article-title":"Effect of thyrotropin suppression therapy on bone in thyroid cancer patients","volume":"21","author":"Papaleontiou","year":"2016","journal-title":"The Oncologist"},{"key":"2021122507523206400_onco12999-bib-0002","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/er.2017-00067","article-title":"Controversies in the management of low-risk differentiated thyroid cancer","volume":"38","author":"Haymart","year":"2017","journal-title":"Endocr Rev"},{"key":"2021122507523206400_onco12999-bib-0003","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1158\/1055-9965.EPI-17-0623","article-title":"Aging-related disease risks among young thyroid cancer survivors","volume":"26","author":"Blackburn","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122507523206400_onco12999-bib-0004","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/thy.2009.0311","article-title":"Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer","volume":"20","author":"Biondi","year":"2010","journal-title":"Thyroid"},{"key":"2021122507523206400_onco12999-bib-0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2021122507523206400_onco12999-bib-0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0169-6009(92)90787-E","article-title":"Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment","volume":"17","author":"Stepan","year":"1992","journal-title":"Bone Miner"},{"key":"2021122507523206400_onco12999-bib-0007","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/BF00834532","article-title":"Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma","volume":"23","author":"G\u00f6rres","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"2021122507523206400_onco12999-bib-0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/eje.1.01933","article-title":"Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive l-thyroxine therapy for differentiated thyroid carcinoma","volume":"153","author":"Heijckmann","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2021122507523206400_onco12999-bib-0009","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.1997.12.1.72","article-title":"Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine","volume":"12","author":"Marcocci","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2021122507523206400_onco12999-bib-0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12020-010-9339-z","article-title":"Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma","volume":"37","author":"Reverter","year":"2010","journal-title":"Endocrine"},{"key":"2021122507523206400_onco12999-bib-0011","doi-asserted-by":"crossref","first-page":"I7","DOI":"10.1097\/00005650-200006001-00002","article-title":"Reinventing va health care: Systematizing quality improvement and quality innovation","volume":"38","author":"Kizer","year":"2000","journal-title":"Med Care"},{"issue":"suppl 1","key":"2021122507523206400_onco12999-bib-0012","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/MLR.0000000000000683","article-title":"Accelerating research impact in a learning health care system: VA's Quality Enhancement Research Initiative in the choice act era","volume":"55","author":"Kilbourne","year":"2017","journal-title":"Med Care"},{"key":"2021122507523206400_onco12999-bib-0013","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1377\/hlthaff.2014.0054","article-title":"Insights from advanced analytics at the veterans health administration","volume":"33","author":"Fihn","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"2021122507523206400_onco12999-bib-0014","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00198-017-3951-1","article-title":"Socioeconomic status and bone mineral density in adults by race\/ethnicity and gender: The Louisiana osteoporosis study","volume":"28","author":"Du","year":"2017","journal-title":"Osteoporos Int"},{"key":"2021122507523206400_onco12999-bib-0015","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00198-011-1736-5","article-title":"Socioeconomic status, race, and bone turnover in the midlife in the us study","volume":"23","author":"Crandall","year":"2012","journal-title":"Osteoporos Int"},{"key":"2021122507523206400_onco12999-bib-0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrendo.2014.51","article-title":"Geographic and ethnic disparities in osteoporotic fractures","volume":"10","author":"Cauley","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"2021122507523206400_onco12999-bib-0017","first-page":"569","article-title":"Diagnosis, and Therapy, March 7-29, 2000: Highlights of the conference","volume":"94","author":"NIH Consensus Development Panel on Osteoporosis Prevention","year":"2001","journal-title":"South Med J"},{"key":"2021122507523206400_onco12999-bib-0018","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1210\/jc.2011-3058","article-title":"Clinical review. Risk factors for low bone mass-related fractures in men: A systematic review and meta-analysis","volume":"97","author":"Drake","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122507523206400_onco12999-bib-0019","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/thy.1995.5.13","article-title":"Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women","volume":"5","author":"Fujiyama","year":"1995","journal-title":"Thyroid"},{"key":"2021122507523206400_onco12999-bib-0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/thy.2014.0287","article-title":"Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma","volume":"25","author":"Wang","year":"2015","journal-title":"Thyroid"},{"key":"2021122507523206400_onco12999-bib-0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0092-8674(03)00812-2","article-title":"TSH, the bone suppressing hormone","volume":"115","author":"Novack","year":"2003","journal-title":"Cell"},{"key":"2021122507523206400_onco12999-bib-0022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodeling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"},{"key":"2021122507523206400_onco12999-bib-0023","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/er.2015-1106","article-title":"Role of thyroid hormones in skeletal development and bone maintenance","volume":"37","author":"Bassett","year":"2016","journal-title":"Endocr Rev"},{"key":"2021122507523206400_onco12999-bib-0024","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/EJE-09-0139","article-title":"Hyperthyroid levels of tsh correlate with low bone mineral density: The HUNT 2 study","volume":"161","author":"Svare","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2021122507523206400_onco12999-bib-0025","doi-asserted-by":"crossref","first-page":"638727","DOI":"10.1155\/2013\/638727","article-title":"Metabolic and clinical consequences of hyperthyroidism on bone density","volume":"2013","author":"Gorka","year":"2013","journal-title":"Int J Endocrinol"},{"key":"2021122507523206400_onco12999-bib-0026","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/jbmr.2416","article-title":"The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: An observational register-based time-resolved cohort analysis","volume":"30","author":"Abrahamsen","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2021122507523206400_onco12999-bib-0027","first-page":"480","article-title":"Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine","volume":"10","author":"Karner","year":"2005","journal-title":"Eur J Med Res"},{"key":"2021122507523206400_onco12999-bib-0028","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/jbmr.3407","article-title":"J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: A retrospective cohort study","volume":"33","author":"Shin","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2021122507523206400_onco12999-bib-0029","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1210\/jc.2013-1332","article-title":"Prevalence and predictors of low bone mineral density in males with ulcerative colitis","volume":"98","author":"Khan","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0234","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0234","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1166\/41918166\/oncolo_24_9_1166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/9\/1166\/41918166\/oncolo_24_9_1166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:53:51Z","timestamp":1640418831000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/9\/1166\/6439328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,6,4]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0234","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,6,4]]}}}